tbuckley/cabot-search huggingface dataset:
Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies
Authors: Johanna Maria Maassen, Raquel Dos Santos Sobrín, Sytske Anne Bergstra, Robbert Goekoop, Tom W J Huizinga, Cornelia F Allaart
Journal: Annals of the Rheumatic Diseases (2021)

To evaluate the success rate of glucocorticoid discontinuation and to study which factors are associated with successful discontinuation.Data from two treat-to-target studies, BeSt (target Disease Activity Score (DAS) ≤2.4) and IMPROVED (target DAS <1.6), were evaluated for all patients initially treated with a tapered high dose of prednisone with conventional synthetic disease-modifying antirheumatic drugs. Prednisone was discontinued when DAS ≤2.4 was maintained for 28 weeks in BeSt and as soon as DAS was <1.6 in IMPROVED. Discontinuation was considered successful if the target was maintained at the next visit. Logistic regression analyses were performed to identify predictors of successful discontinuation. A mixed effects logistic regression model was used to assess whether primary versus secondary discontinuation was as successful.In the BeSt study, 40% (47 of 93) of patients flared after primary prednisone discontinuation, and of the other 60% (56 of 93), 38% had to restart later. Of those who restarted (secondary discontinuation), 47% (17 of 35) again flared. In IMPROVED, after primary discontinuation 39% (158 of 400) flared, and of the other 61% (242 of 400), 40% had to restart later. After secondary discontinuation 49% (68 of 139) flared. Only in IMPROVED a secondary attempt was less successful (BeSt OR 0.71, p=0.45; IMPROVED OR 0.60, p=0.01). A lower DAS both at baseline and stop visit and male gender (in IMPROVED) were associated with successful primary discontinuation.Primary glucocorticoid discontinuation resulted in direct loss of disease control in approximately 40% and secondary in 50% of patients. 'Standard' baseline characteristics seem insufficient to personalise the duration of temporary glucocorticoid bridging, but the DAS at the time of discontinuation might provide guidance.
Abstract 196: Cardiac Small Extracellular Microvesicles-Induced Adipogenesis Suppression Contribute to Matabolic Disorders in Heart Failure
Authors: Lu Gan, Dina Xie, Jing Liu, Demin Liu, Ling Zhang, Zhen Zhang, Erhe Gao, Wayne Bond LAU, Bernard L Lopez, Theodore Christopher, Yajing Wang, Xin L Ma
Journal: Circulation (2019)

Objective: Local and systemic metabolic disorders during heart failure (HF) affecting the disease progression and prognosis. The long-range organ-to-organ communications mediates the coordination of organs homeostasis and adaptation. However, it remains unknown whether and how the failing heart contributes to the adipose dysfunction. Method and Results: 6-8 week-old adult wild type (WT) male mice were subjected to myocardial infraction (MI) for 8 weeks. The cardiac function was evaluated by echocardiography. The plasma lipid profiles were evaluated in Sham and HF mice via Alere LDX analyzer. Interestingly, white adipose tissue weight was significantly decreased, TC/HDL ratio and LDL levels were increased in HF mice compared to non-MI sham mice. To determine the possible pathological mediator, the sEV of murine serum, heart tissue perfusate and cardiomyocyte culture medium from HF mice were isolated and incubated with adipocytes (3T3L1). The adipogenesis was significantly inhibited when sEV isolated from three different resources were administrated to 3T3L1 adipocytes. Pathway specific discover-driven approach revealed that Pparg, Cebpa and Cebpd expression were significantly inhibited by sEV derived from HF cardiomyocytes. To determine the specific mediators in sEV, Venn diagraph assay were performed with two databases (the cardiomyocyte-enriched miRNAs and adipocyte development-related miRNAs). The cluster of miR-23-27-24 and the miR-30 family were markedly elevated in serum-derived, heart tissue-derived and cardiomyocyte-derived sEV from MI mice compared to Sham mice. These changes were validated by RT-qPCR assay. Treatment with miR-23-27-24 significantly inhibited adipogenesis. Conclusion: Taken together, microRNAs miR-23-27-24 and the miR-30 in cardiac-derived sEV are the key messengers facilitating adipocyte dysfunction after MI. Adiogenesis suppression is regulated by failing myocardium-derived sEV, which results in progressive matabolic disorders in the adipose tissue.
POS0785 CHANGING EXPRESSION PROFILES OF LONG NONCODING RNAS, MIRNAS, MRNAS AND CIRCULAR RNAS IN LABIAL SALIVARY GLANDS OF PRIMARY SJÖGREN’S SYNDROME (PSS)
Authors: G. Feng, L. Huang, J. Ji, C. Dong, Y. Xia, C. Cheng, Z. Gu
Journal: Annals of the Rheumatic Diseases (2021)

Background: Primary Sjögren’s syndrome (pSS) is a relatively common autoimmune disease characterized by oral and ocular dryness. An increasing number of studies have revealed that long non-coding RNA (lncRNA), miRNA, mRNA and circular RNA (circRNA) contributes to the pathogenesis of autoimmune diseases. Objectives: To explore lncRNA, miRNA, mRNA and circRNA expression profiles in labial salivary glands (LSGs) in pSS patients and their biological functions in the regulation of pSS. Methods: The expression of 75,550 lncRNAs, 2,318 miRNA, 20,292 mRNAs and 6,877 circRNAs were determined in the LSG of six pSS patients and six healthy controls using microarray experiments. Validation was performed in pSS patients and controls using real-time PCR. LncRNA-mRNA co-expression and gene-pathway networks were constructed using bioinformatics software. Results: A total of 599 lncRNAs (upregulated: 279, downregulated: 320), 78 miRNAs (upregulated: 26, downregulated: 52), 615 mRNAs (upregulated: 590, downregulated: 25) and 160 mRNAs (upregulated: 110, downregulated: 50) were differentially expressed in the LSGs of pSS patients. Five of these lncRNAs were validated using real-time PCR. lncRNA HCP5, lncRNA SNHG5, lncRNA IFI44L, lncRNA CMPK2 were significantly upregulated and lncRNA TTYH1 were downregulated in pSS. GO and KEGG biological pathway analysis were performed to predict the functions of differentially expressed lncRNAs and co-expressed potential targeting genes. Subsequently, a ceRNA (lncRNA-miRNA-mRNA) network including 2320 ceRNA pairs was constructed based on predicted miRNAs shared by lncRNAs and mRNAs. Conclusion: The expression profile provided a systematic perspective on the potential functions of lncRNAs miRNAs, mRNAs and circRNAs in the pathogenesis of pSS. Therefore, this study will aid in the development of new diagnostic biomarkers and drug therapies. References: [1]Le Dantec C, Varin MM, Brooks WH, Pers JO, Youinou P, Renaudineau Y. Epigenetics and Sjogren’s syndrome.Curr Pharm Biotechnol. 2012 Aug;13(10):2046-53. Disclosure of Interests: None declared
Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One
Authors: Karilyn T.M. Larkin, John C. Byrd
Journal: Cancer Discovery (2021)

Abstract Summary: In this issue of Cancer Discovery, Pullarkat and colleagues present the results from a phase I clinical trial that is the first to combine small-molecule inhibitors for multiple antiapoptotic proteins, BCL2 as well as BCL-XL, with a traditional chemotherapy backbone for patients with relapsed/refractory acute lymphoblastic leukemia. This trial has demonstrated impressive response rates with acceptable toxicity while providing proof of concept that dual targeting—hitting BCL2 hard and BCL-XL soft—is both effective and tolerable in a heterogeneous patient population with prior existing cytopenias. See related article by Pullarkat et al., p. 1440.
Lipoprotein(a) Measurement in Clinical Practice—Reply
Authors: Ludovico Furlan, Patrick Azcarate, Rita F. Redberg
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial
Authors: Boris Revollo, Ignacio Blanco, Pablo Soler, Jessica Toro, Nuria Izquierdo-Useros, Jordi Puig, Xavier Puig, Valentí Navarro-Pérez, Cristina Casañ, Lidia Ruiz, Daniel Perez-Zsolt, Sebastià Videla, Bonaventura Clotet, Josep M Llibre
Journal: The Lancet Infectious Diseases (2021)

The banning of mass-gathering indoor events to prevent SARS-CoV-2 spread has had an important effect on local economies. Despite growing evidence on the suitability of antigen-detecting rapid diagnostic tests (Ag-RDT) for mass screening at the event entry, this strategy has not been assessed under controlled conditions. We aimed to assess the effectiveness of a prevention strategy during a live indoor concert.
Multimodally profiling memory T cells from a tuberculosis cohort identifies cell state associations with demographics, environment and disease
Authors: Aparna Nathan, Jessica I. Beynor, Yuriy Baglaenko, Sara Suliman, Kazuyoshi Ishigaki, Samira Asgari, Chuan-Chin Huang, Yang Luo, Zibiao Zhang, Kattya Lopez, Cecilia S. Lindestam Arlehamn, Joel D. Ernst, Judith Jimenez, Roger I. Calderón, Leonid Lecca, Ildiko Van Rhijn, D. Branch Moody, Megan B. Murray, Soumya Raychaudhuri
Journal: Nature Immunology (2021)
Hypoxia-induced lncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/ 1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway
Authors: Guanghui Hu, Junjie Ma, Jin Zhang, Yonghui Chen, Huan Liu, Yiran Huang, Junhua Zheng, Yunfei Xu, Wei Xue, Wei Zhai
Journal: Molecular Therapy (2021)

Hypoxia has been identified as a common contributor to tumor progression, including invasion and metastasis. However, the underlying mechanisms of enhanced invasion and metastasis under hypoxia remain unclear. A hypoxic microenvironment promotes invasion and metastasis of renal cell carcinoma (RCC) by upregulating expression of LOC100506178, which we named hypoxia-induced long non-coding RNA (lncRNA) associated with RCC (lncHILAR). Knockdown of lncHILAR inhibited cell invasion and migration, whereas overexpression of lncHILAR, conversely, facilitated cell invasion and migration of RCC cells. Notably, hypoxic RCC cells secreted exosomes packaged with lncHILAR, which were taken up by normoxic RCC cells and then drove normoxic cell invasion. Mechanistically, lncHILAR elevated RCC invasion and metastasis by acting as a competing endogenous RNA (ceRNA) for miR-613/206/1-1-3p, which led to the upregulation of Jagged-1 and the C-X-C motif chemokine receptor 4 (CXCR4). Activation of the Jagged-1/Notch/CXCR4 axis induced RCC metastasis. lncHILAR promotes RCC cell invasion and metastasis via ceRNA for the miR-613/206/1-1-3p/Jagged-1/Notch/CXCR4 axis. The novel lncHILAR may thus serve as a potential biomarker and therapeutic target in RCC.
Abstract 15716: Prediction for Atrial Fibrillation Recurrence After Catheter Ablation Using an Artificial Intelligence-Assisted Coronary Sinus Electrogram
Authors: Zijie Zhang, Kaibin Lin, Zhaorui Zuo, Dahong Qian, Yuting Xie, Dong Huang, Jingbo Li
Journal: Circulation (2019)

Background: Atrial fibrillation (AF) is the most common tachycardia with significant adverse outcomes and catheter ablation is a widely adopted treatment. However, some of patients who underwent th...
OP0004 AUTOIMMUNE AND INFLAMMATORY MANIFESTATIONS IN COMMON VARIABLE IMMUNODEFICIENCY DISORDERS
Authors: K. López-Aldabe, L. Hidalgo, A. Antolí, G. Rocamora, X. Corbella, X. Solanich
Journal: Annals of the Rheumatic Diseases (2021)

Background: Common variable immunodeficiency (CVID) disorders are the second most frequent immunodeficiency worldwide and autoimmune diseases (AD) are present in 20% of such patients, cytopenia being the most frequent manifestation [1]. Defects in central and peripheral tolerance, activation/proliferation of B cells, and hypogammaglobulinemia are key features of the disease, along with a reduction in CD4+T cells, abnormalities in Treg and defective secretion of regulatory cytokines, that could perpetuate autoimmune - autoinflammatory phenomena. Objectives: To describe immune and inflammatory disorders in our CVID cohort. Methods: Retrospective analysis of 33 patients who fulfill the European Society for Immunodeficiencies (ESID) Registry – Work criteria for CVID diagnosis [2] treated in the immunodeficiency unit of our tertiary university hospital. After getting an informed consent form, medical records were revised to obtain clinical, analytical and immunological data. Results: Of the 33 CVID patients analysed, 11 had some autoimmune/inflammatory manifestation. Seven patients presented autoimmune thrombocytopenia (AIT), and one of them also had non-severe neutropenia. Two patients also had seronegative spondyloarthropathy, one patient had cutaneous psoriasis, and two patients had alopecia. There were no cases of type 1 diabetes, vitiligo or thyroid disorders. Interestingly, four patients had lung involvement, two of them with granulomatous-lymphocytic interstitial lung disease (GLILD), one with organising pneumonia and one with usual interstitial pneumonia. Five of the eleven patients required immunosuppressive treatment, mostly with steroids. One case of AIT required concomitant treatment with azathioprine and the patient with psoriasis was treated with methotrexate. In six patients, autoimmune disorder was the first manifestation. Conclusion: 33% of the CVID patients had autoimmune or inflammatory manifestations in our cohort; six patients had one immune/inflammatory phenomena, four had two different disorders and one patient presented with three different ones. The most frequent manifestation was AIT, as seen in previous reports. In six cases, the autoimmune-inflammatory manifestation was the first symptom attributable to CVID. In conclusion, AD are common in CVID patients, so clinicians must be aware of possible immunodeficiencies in this type of patients. References: [1]Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. Primary immunodeficiency and autoimmunity: A comprehensive review. J Autoimmun. 2019 May;99:52-72. [2]ESID Registry – Working Definitions for Clinical Diagnosis of PID, January 22, 2019. Disclosure of Interests: None declared
AB0663 COMPARING METHODS FOR DETERMINING ANTIBODIES TO SARS-CoV-2 USING A RAPID TEST AND ENZYME-LINKED IMMUNOSORBENT ASSAY
Authors: G. Gridneva, E. Aronova, S. Glukhova, M. Cherkasova, B. Belov, K. Nurbaeva, E. Salyanova
Journal: Annals of the Rheumatic Diseases (2021)

Background: An accessible and sensitive and sensitive method for determining antibodies to a new coronavirus infection is often the key to timely provision of the necessary medical care to patients with rheumatic diseases Objectives: Compare methods for determining antibodies to SARS-CoV-2 using a rapid test and enzyme-linked immunosorbent assay (ELISA) Methods: Methods for determining antibodies to SARS-CoV-2 using an express test (Chromatographic express test SARS-CoV-2 IgG / IgM (Xiamen Biotime Biotechnology, China)) and by ELISA (Reagent kit for enzyme immunoassay of class G immunoglobulins and class M to SARS-CoV-2 (Vector-Best, Russia)) were compared. 80 patients were included with a diagnosis of rheumatoid arthritis 26 (33%), psoriatic arthritis - 9 (11%), osteoarthritis - 15 (19%), rheumatic heart disease 1 (1%), SLE 2 (3%), deramtomyositis 3 (4%), systemic sclerosis 5 (6%), systemic connective tissue diseases 4 (5%), including Sjogren’s syndrome, spondyloarthritis 15 (19%). 17 (21%) denied a history of COVID-19 symptoms. 63 (79%) noted any signs of COVID-19 3.095 ± 1.45 months before the test (Median 3 [2; 4] months). 63 (79%) noted any signs of COVID-19 109 ± 43 days before the test (Median 111 [78; 135] months). The ELISA method was considered the standard. Results: When comparing the results of the express test and the determination of IgG antibodies to SARS-CoV-2 in serum, the following was obtained: the sensitivity of the express test is 99%. When comparing the results of the express test and the determination of IgM antibodies to SARS-CoV-2 in serum, it was obtained: among 66 samples with a negative result by the express test method, IgM was detected in 6 cases by ELISA/ So, 7.5% of 80 samples were false negative. In 3 of 14 samples with a positive result by the express test, IgM by ELISA was not detected. So, 3.75% of 80 samples were false-positive. (Table 1). When comparing the results of the IgM express test and ELISA, the following was obtained: the sensitivity of the express test was 33%, the specificity was 85%. Table 1. Antibodies, express-test Antibodies (ELISA), absent Antibodies (ELISA), present Row Totals IgG absent 0 1 1 Row % 0.00% 100.00% present 3 76 79 Row % 3.80% 96.20% Totals 3 77 80 IgМ absent 60 6 66 Row % 90.91% 9.09% present 11 3 14 Row % 78.57% 21.43% Totals 71 9 80 Conclusion: When comparing the results of the express test and the determination of IgG antibodies to SARS-CoV-2 in serum, the sensitivity of the express test is 99%. Determination of IgM antibodies to SARS-CoV-2 using a rapid test is less reliable than determination using ELISA. Disclosure of Interests: None declared.
Preoptic BRS3 neurons increase body temperature and heart rate via multiple pathways
Authors: Ramón A. Piñol, Allison S. Mogul, Colleen K. Hadley, Atreyi Saha, Chia Li, Vojtěch Škop, Haley S. Province, Cuiying Xiao, Oksana Gavrilova, Michael J. Krashes, Marc L. Reitman
Journal: Cell Metabolism (2021)
Legislation to Criminalize Gender-Affirming Medical Care for Transgender Youth
Authors: Jack L. Turban, Katherine L. Kraschel, I. Glenn Cohen
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US Hospital Data About Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses
Authors: Marjorie Meyer, Jerilyn Metayer
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
POS0841 RISK FACTORS OF LOW BONE MINERAL DENSITY IN WOMEN WITH SYSTEMIC SCLEROSIS
Authors: A. Efremova, N. Toroptsova, N. Demin, O. Dobrovolskaya, O. Nikitinskaya
Journal: Annals of the Rheumatic Diseases (2021)

Background: Chronic inflammatory rheumatic diseases are risk factors of bone loss and fractures. Systemic sclerosis (SSc) has been recognized to be another potential inflammatory joint disease that may affect bone tissue. Objectives: to evaluate bone mineral density (BMD) and risk factors of low BMD in women with SSc. Methods: 173 women, among them 110 postmenopausal (median age 60[55,63] years) and 63 premenopausal (median age 35[31,44] years). BMD was measured at lumbar spine (LS), femoral neck (FN) and total hip (TH) by dual energy X-ray absorptiometry (DXA, Hologic 4500A). Low BMD was diagnosed if the T-score was &lt; -1.0 standard deviation (SD) in postmenopausal women and if the Z-score was &lt; -2.0 SD in premenopausal women. The relationship between BMD and SSc patients’ characteristics was evaluated using univariate linear regression analysis. Results: Low BMD was found in 66% patients: 79% - in postmenopausal and 18% - in premenopausal women. Among postmenopausal persons osteoporosis was discovered in 47% and osteopenia – in 32% cases. In postmenopausal woman BMD of LS, FN and TH were associated with body mass index (BMI) (β=0.27, p=0.010; β=0.47, p&lt;0,001 and β=0.45, p&lt;0,001, respectively), duration of glucocorticoids (GCs) using (β=-0.31, p=0.008; β=-0.34, p=0.003 and β=-0.27, p=0.022, respectively); BMD of FN and TH with C-reactive protein (β= -0.32, p=0.016 and β= -0.29, p=0.029, respectively) and LS BMD with current and cumulative GCs dose (β= -0.24, p=0.039 and β= -0.29, p=0.014, respectively). In premenopausal women BMD of LS, FN and TH were associated with BMI (β=0.51, p&lt;0,001; β=0.45, p=0.003 and β=0.47, p=0.002, respectively), duration of GCs using (β= -0.45, p=0.004; β= -0.47, p=0.003 and β= -0.48, p=0.002, respectively) and GCs cumulative dose (β= -0.48, p=0.002; β= -0.51, p=0.001 and β= -0.46, p=0.004, respectively); BMD of FN and TH with 25(ОН)D level (β=0.52, p=0.008 and β=0.54, p=0.005, respectively), and LS BMD with SSc duration (β= -0.44, p=0.004). Conclusion: Low BMD was diagnosed in 66% of women with SSc. Low BMI, GCs cumulative dose and duration of GCs using were independent risk factors for low BMD in both premenopausal and postmenopausal persons. Additional factors as SSc duration and low vitamin D level were found out for premenopausal and current GCs dose and C-reactive protein level for postmenopausal women. Disclosure of Interests: None declared